Evidence map›Paper›PMID 32397206›Full record

ArticleCancers2020

Chromenopyrimidinone Controls Stemness and Malignancy by suppressing CD133 Expression in Hepatocellular Carcinoma.

Yeonhwa Song, Sanghwa Kim, Hyeryon Lee, Joo Hwan No, Hyung Chul Ryu, Jason Kim, Jee Woong Lim, Moonhee Kim, Inhee Choi, Haeng Ran Seo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. The role of CD133 in hepatocellular carcinoma.Cancer biology & therapy · 2021
    Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yeonhwa SongCancer Biology Laboratory, Institut Pasteur Korea, Seongnam-si 13488, Korea.
Sanghwa KimCancer Biology Laboratory, Institut Pasteur Korea, Seongnam-si 13488, Korea.
Hyeryon LeeLeishmania Research Laboratory, Institut Pasteur Korea, Seongnam-si 13488, Korea.
Joo Hwan NoLeishmania Research Laboratory, Institut Pasteur Korea, Seongnam-si 13488, Korea.
Hyung Chul RyuR&D Center, J2H Biotech, Suwon-si 16648, Korea.
Jason KimR&D Center, J2H Biotech, Suwon-si 16648, Korea.
Jee Woong LimR&D Center, J2H Biotech, Suwon-si 16648, Korea.
Moonhee KimR&D Center, J2H Biotech, Suwon-si 16648, Korea.
Inhee ChoiMedicinal Chemistry, Institut Pasteur Korea, Seongnam-si 13488, Korea.
Haeng Ran SeoCancer Biology Laboratory, Institut Pasteur Korea, Seongnam-si 13488, Korea.
Institut Pasteur Korea · KRSTR Biotech (South Korea) · KR

Funding

National Research Foundation of Korea Authors should obtain permission to reproduce any published material (figures, schemes, tables, or any extract of a text) that does not fall into the public domain, or for which they do not hold the copyright. Permission should be requested by the authorsNational Research Foundation of Korea NRF-2017M3A9G6068246National Research Foundation of Korea NRF-2017M3A9G7072864
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a highly malignant human cancer that has increasing mortality rates worldwide. Because CD133

Indexed as

CD133chromenopyrimidinone (CPO)hepatocellular carcinoma (HCC)liver cancer stem cells (LCSCs)UBE2C

Identifiers

PMID32397206
PMCPMC7281429
OpenAlexW3023481676

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.